Feature | Intra-Aortic Balloon Pumps (IABP) | July 24, 2019

Datascope Recalls Intra-Aortic Balloon Pumps Due to Potential Battery Failure

FDA Class I recall includes the Cardiosave Hybrid, Cardiosave Rescue, CS300 and CS100/100i IABP 

Datascope Recalls Intra-Aortic Balloon Pumps Due to Potential Battery Failure. FDA Class I recall includes the Cardiosave Hybrid, Cardiosave Rescue, CS300 and CS100/100i IABP.

July 24, 2019 — The U.S. Food and Drug Administration announced Maquet/Datascope is recalling all intra-aortic balloon pumps (IABP) due to reports of the batteries failing to hold a charge, stopping unexpectedly and having a shortened run-time. This may cause the device to stop working when being operated by battery only. The FDA issued a recall notice that said if a patient requires life-supporting therapy with an IABP and the device does not work or if therapy is stopped during use due to battery failure, the patient will be at risk of serious injury, including death.

Maquet/Datascope is aware of five patient deaths since March 2016, although the firm has not concluded that the deaths are due solely to the device shutting down while operating on battery power, the FDA said. The company said the recall includes 22,853 devices in the United States.

Last November, the FDA issued a warning letter explaining it was evaluating reports of Getinge's Maquet/Datascope IABP devices shutting down while running on battery power. The company issued a letter to providers warning them about this issue Nov. 1, 2018. The warning has now been elevated to a full recall.

This FDA Class I recall is being conducted to ensure that all IABP users and servicers follow each device's operating instructions manual for recommendations on usage, charging, maintenance and storage of the batteries, as battery run times and discharge cycles vary between IABP models. If battery maintenance is not performed per the operating instructions manual for each IABP, the battery may not provide the expected minimum run time of operating power.

The recall includes the following Maquet/Datascope IABP models. This includes all lot numbers and manufacturing dates:
   • Cardiosave Hybrid IABP
   • Cardiosave Rescue IABP
   • CS300 IABP
   • CS100/100i IABP

The Maquet/Datascope IABPs are cardiac assist devices used with patients undergoing cardiac and non-cardiac surgery, and to treat patients with acute coronary syndrome or complications from heart failure.

Corrective Action to Prevent IABP Battery Failure

On June 17, 2019, Maquet/Datascope sent affected customers an "Urgent Medical Device Correction" notice informing them of the potential risk of battery failure and listing actions that should be taken to minimize patient harm. The vendor is contacting each customer to schedule a training visit to review a recently developed battery operations, care and maintenance reference guide specific to each IABP based on the operating instructions manual(s) provided with each device. The company said no product returns are required.

The notice instructed customers to:

   • Ensure the IABP is plugged into an AC power outlet when the system is not in use and whenever possible during patient use.
   • Refer to the IABP operating instructions manual for recommendations on portable/battery operation when transporting patients within or between facilities.

For the Cardiosave Rescue and Cardiosave Hybrid IABPs only:
   • Have additional charged batteries on hand during transport.
   • Ensure the batteries are properly seated in the battery compartment/charger and the IABP console is completely seated/secured into the IABP cart.
   • For the Cardiosave Hybrid, users can verify if the console is completely seated in the IABP cart by the indicator on the display.
   • Check battery run time and replace batteries as required, as recommended in each IABP's Operating Instructions Manual.

Batteries should be replaced:
   • After reaching the maximum number of charge-discharge cycles.
   • When the battery provides less than the minimum specified run time.
   • If the battery is broken, cracked, leaking or damaged.
   • When the labeled lifetime of the battery is reached.

The company said batteries for the Cardiosave Hybrid and Cardiosave Rescue IABPs sold before June 2015 should be replaced immediately as the labeled lifetime for these batteries is four years. Replacement batteries can be ordered through a sales or service representative. To determine the date of manufacture for all Cardiosave batteries, refer to the document, "Cardiosave Lithium-ion Battery Pack" ML-0795 in the "Urgent Medical Device CorrectionExternal Link Disclaimer" notice.   

For CS100/CS300 systems, informational messages on the display screen provide information to the operator regarding the batteries. The "battery maintenance required" message indicates that the IABP internal battery requires maintenance. The battery test due date or battery replacement date predate the current system date at startup or the internal battery has a total accumulated discharge time in excess of 100 total discharge cycles.

Ensure only Datascope approved or sourced batteries are installed and used for all replacement batteries.

Users can complete and return page 4 of the "Urgent Medical Device Correction Form" by fax to 1-866-340-5660, or email at: [email protected]

Maquet/Datascope is currently developing a Cardiosave battery maintenance software upgrade targeted for early 2020. This updated software requires FDA clearance and once completed, a Maquet/Datascope service representative will contact customers to schedule the installation of the updated software at no cost.

A similar software upgrade was released for the CS300 IABP and CS100 IABP in 2017. If operators are unsure whether their IABP has been updated with the released software upgrade, they can contact Maquet/Datascope Technical Support Department with the model and serial number of the IABP.

Customers with questions about this device correction may contact Maquet/Datascope Technical Support Department at 1-888-627-8383 (select option "3") from 8 a.m. - 6 p.m.(Eastern Time), Monday through Friday.

 

Links to the Getting Resources For Customers:
   • Datascope Urgent Medical Device Correction Notice (June 17, 2019)External Link Disclaimer
   • Datascope Cardiosave, CS100 and CS300 Battery Quick Reference GuidesExternal Link Disclaimer

 

Links to the FDA Class 1 Recall Notices:

Class 1 Device Recall Cardiosave Hybrid IntraAortic Balloon Pump

Class 1 Device Recall Cardiosave Rescue IntraAortic Balloon Pump

Class 1 Device Recall CS100 IntraAortic Balloon Pump

Class 1 Device Recall CS300 IntraAortic Balloon Pump

 

Related IABP Content:
Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump
Maquet/Datascope Intra-Aortic Balloon Pumps Might Fail on Battery Power

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021